One-off factors knock Takeda to operating loss
This article was originally published in Scrip
Executive Summary
After further digesting the impact of its recent acquisition of Millennium Pharmaceuticals and the dissolution of the TAP Pharmaceutical joint venture with Abbott in the US, Takedahas added ¥40 billion ($370.7 million) to its earlier forecasts for operating and net profit this fiscal year.